The Future of Surgical Management of Inflammatory Bowel Disease
暂无分享,去创建一个
[1] A. Michalsen,et al. Noninvasive Markers in the Assessment of Intestinal Inflammation in Inflammatory Bowel Diseases: Performance of Fecal Lactoferrin, Calprotectin, and PMN-Elastase, CRP, and Clinical Indices , 2008, The American Journal of Gastroenterology.
[2] E. Loftus,et al. Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment? , 2007, Inflammatory bowel diseases.
[3] A. Griffiths,et al. Hepatosplenic T‐cell lymphoma in adolescents and young adults with Crohn's disease: A cautionary tale? , 2007, Inflammatory bowel diseases.
[4] E. Toth,et al. Role of chromoendoscopy in colon cancer surveillance in inflammatory bowel disease , 2007, Inflammatory bowel diseases.
[5] Alastair Forbes,et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility , 2007, Nature Genetics.
[6] R. Summers. Novel and future medical management of inflammatory bowel disease. , 2007, The Surgical clinics of North America.
[7] P. Banks,et al. Section editor's commentary. The role of panca and asca in differentiating ulcerative colitis, Crohn's disease, and indeterminate colitis , 2007 .
[8] Philippe Goyette,et al. Molecular pathogenesis of inflammatory bowel disease: Genotypes, phenotypes and personalized medicine , 2007, Annals of medicine.
[9] S. Targan,et al. Recent understanding of IBD pathogenesis: Implications for future therapies , 2006, Inflammatory bowel diseases.
[10] Judy H. Cho,et al. Genetic advances in inflammatory bowel disease , 2006, Current treatment options in gastroenterology.
[11] I. Buchan,et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. , 2006, JAMA.
[12] W. Koltun. Editorial: Imaging and Robotics in Surgical Practice , 2005 .
[13] R. Duerr,et al. Innate Immune Receptor Genetic Polymorphisms in Pouchitis: Is CARD15 a Susceptibility Factor? , 2005, Inflammatory bowel diseases.
[14] Mourad Sahbatou,et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease , 2001, Nature.
[15] Judy H. Cho,et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease , 2001, Nature.
[16] R. Macdermott. Lack of current clinical value of serological testing in the evaluation of patients with IBD. , 1999, Inflammatory bowel diseases.
[17] S. Targan. The utility of ANCA and ASCA in inflammatory bowel disease. , 1999, Inflammatory bowel diseases.
[18] P. Banks,et al. The Role of pANCA and ASCA in Differentiating Ulcerative Colitis, Crohnʼs Disease, and Indeterminate Colitis , 1999 .
[19] W. Koltun,et al. Techniques of disease activity assessment in Crohn's disease , 2001 .